Další formáty:
BibTeX
LaTeX
RIS
@article{1299692,
author = {Schiffman, S.C. and Metzger, T. and Dubel, G. and Andrašina, Tomáš and Kralj, I. and Tatum, C. and McMasters, K.M. and Scoggins, C.R. and Martin, R.C.G.},
article_location = {NEW YORK},
article_number = {2},
doi = {http://dx.doi.org/10.1245/s10434-010-1333-4},
keywords = {Hepatic Arterial Irinotecan Therapy; Unresectable Intrahepatic Cholangiocellular Carcinoma},
language = {eng},
issn = {1068-9265},
journal = {Annals of Surgical Oncology},
title = {Precision Hepatic Arterial Irinotecan Therapy in the Treatment of Unresectable Intrahepatic Cholangiocellular Carcinoma: Optimal Tolerance and Prolonged Overall Survival},
volume = {18},
year = {2011}
}
TY - JOUR
ID - 1299692
AU - Schiffman, S.C. - Metzger, T. - Dubel, G. - Andrašina, Tomáš - Kralj, I. - Tatum, C. - McMasters, K.M. - Scoggins, C.R. - Martin, R.C.G.
PY - 2011
TI - Precision Hepatic Arterial Irinotecan Therapy in the Treatment of Unresectable Intrahepatic Cholangiocellular Carcinoma: Optimal Tolerance and Prolonged Overall Survival
JF - Annals of Surgical Oncology
VL - 18
IS - 2
SP - 431-438
EP - 431-438
PB - SPRINGER
SN - 10689265
KW - Hepatic Arterial Irinotecan Therapy
KW - Unresectable Intrahepatic Cholangiocellular Carcinoma
N2 - Unresectable intrahepatic cholangiocellular carcinoma (ICC) carries a poor prognosis, and there are few chemotherapeutic treatments to prolong survival. The purpose of this study was to assess the efficacy of drug-eluting bead (DEB) therapy by transarterial infusion for unresectable ICC. A prospective multicenter study of ICC patients who received hepatic arterial DEB therapy. Twenty-four patients with unresectable ICC were treated with DEB. Ten patients (41.6%) had recurrent ICC after prior radiofrequency ablation (n = 3) or hepatectomy (n = 7). Twenty patients (80%) had received prior chemotherapy, mostly of gemcitabine (n = 8) or Eloxatin (n = 6). The percent of overall liver involvement was < 25% (n = 8), 26% to 50% (n = 11), and > 50% (n = 4). Ten patients (40%) had sites of extrahepatic disease located at lymph nodes (n = 5), bone (n = 2), peritoneum (n = 1), lung (n = 1), and mouth (n = 1). A total of 42 DEB treatments were administered. Eight were administered in combination with systemic chemotherapy of FOLFOX (n = 4) or Gemzar (n = 4). Twelve patients (48%) received a second treatment, and 4 patients (16%) received a third treatment. The median length of stay was 23 h (23-72 h). Eleven adverse reactions (26.2%) were reported. Of these, 7 (63.6%) were minor (less than grade 3). One patient died from hepatorenal syndrome. The disease of one patient was downstaged to resection. After a median follow-up of 13.6 months, the median overall survival of a multitherapeutic regimen with DEB therapy was significantly greater than chemotherapy alone (17.5 vs. 7.4 months; P = 0.02). Bead therapy is safe and effective in patients with unresectable ICC. There is a marked survival benefit when DEB therapy is used as adjunctive therapy.
ER -
SCHIFFMAN, S.C., T. METZGER, G. DUBEL, Tomáš ANDRAŠINA, I. KRALJ, C. TATUM, K.M. MCMASTERS, C.R. SCOGGINS a R.C.G. MARTIN. Precision Hepatic Arterial Irinotecan Therapy in the Treatment of Unresectable Intrahepatic Cholangiocellular Carcinoma: Optimal Tolerance and Prolonged Overall Survival. \textit{Annals of Surgical Oncology}. NEW YORK: SPRINGER, 2011, roč.~18, č.~2, s.~431-438. ISSN~1068-9265. Dostupné z: https://dx.doi.org/10.1245/s10434-010-1333-4.
|
